Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine.
BACKGROUND
Only unbound or free drug in plasma can be transported to its site of action. The fraction of unbound drug in plasma varies widely for highly bound drugs among individuals. The genetic polymorphism of orosomucoid (ORM) could be related to the interindividual variability in plasma binding of basic drugs, as ORM is the transport protein for these drugs in plasma. The ORM is a major binding protein in plasma for various basic drugs and is coded by two loci, ORM1 and ORM2, which are closely linked on chromosome 9q31-->34.1. ORM1 locus is highly polymorphic and the ORM2 locus is monomorphic in most population.


METHODS
Twenty-eight healthy volunteers were selected with three ORM1 phenotypes, containing homozygotes ORM1 F1 (n=10) and ORM1 S (n=8), and heterozygote ORM1 F1S (n=10), identified by isoelectric focusing on polyacrylamide gels followed immunoblotting after desialylation of sera. After a single oral dose of quinidine 200 mg, serum total (HPLC) and unbound concentrations in ultrafiltrate (ultrafiltration/HPLC) were determined, and the pharmacokinetic parameters and protein binding rate were calculated.


RESULTS
Serum concentrations of ORM (553.8-573.2 mg/l) and albumin proteins (57.5-58.4 mg/l) were similar in the three groups (P>0.05). Unbound quinidine concentration in ORM1 F1 phenotype subjects was higher than that in ORM1 S and ORM1 F1S phenotype; the free drug percentage for the subjects with ORM1 F1 phenotype (19.79%) was twice as high as that with ORM1 S phenotype (10.96%) (P<0.01) at 24 h after administration of oral quinidine when the state of disposition equilibrium occurred. The elimination t(1/2) values and the other pharmacokinetic parameters of quinidine were not affected by the different ORM1 phenotypes.


CONCLUSIONS
Different ORM1 phenotypes may affect the disposition of quinidine, a basic drug, rather than its hepatic metabolism and elimination. The functional heterogeneity of ORM1 could be responsible for the differences in plasma binding of quinidine. Therefore, monitoring of the unbound quinidine concentration would be important for the patients with different ORM1 phenotypes who are treated with quinidine.
Li
Jin Heng
JH
Department of Clinical Pharmacology, Jinling Hospital, Clinical School of Medical College, Nanjing University, 305 East Zhongshan Road, 210002, Nanjing, PR China. ljhengyr@jlonline.com
Xu
Jing Qiu
JQ
Cao
Xiao Mei
XM
Ni
Li
L
Li
Yong
Y
Zhuang
Yi Yi
YY
Gong
Jian Bin
JB
D000328:Adult; D001798:Blood Proteins / Q000378:metabolism; D006579:Heterozygote; D006801:Humans; D008297:Male; D009961:Orosomucoid / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic; D011802:Quinidine / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics
D001798:Blood Proteins; D009961:Orosomucoid; D011802:Quinidine